A brain-permeable CSF-1R inhibitor, pexidartinib (PLX3397) was administered to mice before injection of 4T1-BR5 triple negative breast cancer cells, and significantly reduced brain metastases in young mice [26]. This evidence concerns the gene CSF1R and triple-negative breast carcinoma.